(2025). Selective sodium-glucose cotransporter two inhibitor empagliflozin ameliorates diabetic cardiomyopathy by activating the AMPK/TFEB signaling pathway. Journal of Food and Drug Analysis.
Successfully copied to clipboard
Copying to clipboard failed
Chicago Style (17th ed.) Citation
"Selective Sodium-glucose Cotransporter Two Inhibitor Empagliflozin Ameliorates Diabetic Cardiomyopathy by Activating the AMPK/TFEB Signaling Pathway."
Journal of Food and Drug Analysis 2025.
Successfully copied to clipboard
Copying to clipboard failed
MLA (9th ed.) Citation
"Selective Sodium-glucose Cotransporter Two Inhibitor Empagliflozin Ameliorates Diabetic Cardiomyopathy by Activating the AMPK/TFEB Signaling Pathway."
Journal of Food and Drug Analysis, 2025.
Successfully copied to clipboard
Copying to clipboard failed
Warning: These citations may not always be 100% accurate.